Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Unipolar Voltage-Guided Individualized Substrate Modification Combined With Pulsed Field Ablation-Based Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone in Persistent Atrial Fibrillation: A Multicenter, Randomized, Open-Label, Superiority Trial

NCT07926854 is registered in ClinicalTrials.gov with China National Center for Cardiovascular Diseases as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07926854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Unipolar Voltage-Guided Individualized Substrate Modification Combined With Pulsed Field Ablation-Based Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone in Persistent Atrial Fibrillation: A Multicenter, Randomized, Open-Label, Superiority Trial
Lead sponsor
China National Center for Cardiovascular Diseases
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
December 31, 2029
Enrollment
294 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation (af)

Arms

As registered; 2 arms.

  • PFA-PVI Plus Individualized Substrate Modification ExperimentalIndividualized Substrate Modification, Pulmonary Vein Isolation, VARIPULSE Pulsed Field Ablation System

    Pulsed field ablation (PFA)-based pulmonary vein isolation plus unipolar voltage-guided individualized substrate modification. Substrate modification is selected according to low-voltage area location and may include homogenization, box isolation, linear ablation, or a combination.

  • PFA-PVI Alone Active comparatorPulmonary Vein Isolation, VARIPULSE Pulsed Field Ablation System

    Pulsed field ablation (PFA)-based pulmonary vein isolation alone, without substrate or prophylactic ablation.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Treatment Success at 12 Months After the Index Ablation Procedure 12 months after the index ablation procedure

    Freedom from documented atrial fibrillation, atrial tachycardia, or atrial flutter lasting more than 30 seconds after a 90-day blanking period while off class I/III antiarrhythmic drugs, allowing up to one repeat ablation within 6 months of the index procedure (1-2 procedures total). Patients who remain on class I/III antiarrhythmic drugs at 12 months are counted as treatment failures; missing primary outcome data are counted as treatment failures.

Lead sponsor's other trials

China National Center for Cardiovascular Diseases, most recent start first.

Similar trials

Same condition (Atrial Fibrillation) and phase, most recent start first.